Synergy of Anti-CD40, CpG and MPL in Activation of Mouse Macrophages

Overview

Journal Mol Immunol

Specialties Allergy & Immunology
Molecular Biology

Date 2015 Apr 2

PMID 25829245

Citations 13

Authors

Yongyu Shi

Mildred A R Felder

Paul M Sondel

Alexander L Rakhmilevich

Affiliations

Soon will be listed here.

Abstract

Activation of macrophages is a prerequisite for their antitumor effects. Several reagents, including agonistic anti-CD40 monoclonal antibody (anti-CD40), CpG oligodeoxynucleotides (CpG) and monophosphoryl lipid A (MPL), can stimulate activation of macrophages. Our previous studies showed synergy between anti-CD40 and CpG and between anti-CD40 and MPL in macrophage activation and antitumor efficacy in mice. In the present study, we asked whether there was synergy among these three reagents. The activation of adherent peritoneal exudate cells (PEC) obtained from mice injected with anti-CD40 and then treated with CpG and/or MPL in vitro was determined by their ability to suppress proliferation of tumor cells and to produce various cytokines and chemokines in vitro. Cell sorting and histology followed by functional testing showed that macrophages were the main cell population in PEC activated by CD40 ligation in vivo. A combination of anti-CD40, CpG or MPL activated PEC to suppress proliferation of B16 cells and produce nitric oxide far greater than the single reagents or any of the double combinations of these reagents. In addition, the combination of all three reagents activated PEC to secrete IL-12, IFN-γ and MCP-1 to a greater degree than any single reagent or any two combined reagents. These results demonstrate that macrophages can be synergistically activated by anti-CD40, CpG and MPL, suggesting that this novel combined approach might be further investigated as potential cancer therapy.

Citing Articles

Polysaccharide Induces Apoptosis of B16 Melanoma Cells via Promoting the M1 Polarization of Macrophages.

Xie L, Liu G, Huang Z, Zhu Z, Yang K, Liang Y Molecules. 2023; 28(10).

PMID: 37241759 PMC: 10220659. DOI: 10.3390/molecules28104018.

Translatable Drug-Loaded Iron Oxide Nanophore Sensitizes Murine Melanoma Tumors to Monoclonal Antibody Immunotherapy.

Stater E, Morcos G, Isaac E, Ogirala A, Hsu H, Longo V ACS Nano. 2023; 17(7):6178-6192.

PMID: 36971591 PMC: 10324163. DOI: 10.1021/acsnano.2c05800.

Radiation Augments the Local Anti-Tumor Effect of Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models.

Pieper A, Zangl L, Speigelman D, Feils A, Hoefges A, Jagodinsky J Front Immunol. 2021; 12:763888.

PMID: 34868010 PMC: 8634717. DOI: 10.3389/fimmu.2021.763888.

Immunomodulatory and anti-inflammatory effects of Phellinus linteus mycelium.

Shin M, Lee J, Lee J, Kim M, Park H, Park B BMC Complement Med Ther. 2021; 21(1):269.

PMID: 34702240 PMC: 8547106. DOI: 10.1186/s12906-021-03441-9.

Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages.

Reis-Sobreiro M, Teixeira da Mota A, Jardim C, Serre K Cells. 2021; 10(9).

PMID: 34572013 PMC: 8464913. DOI: 10.3390/cells10092364.

References

Buhtoiarov I, Lum H, Berke G, Paulnock D, Sondel P, Rakhmilevich A . CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol. 2005; 174(10):6013-22. DOI: 10.4049/jimmunol.174.10.6013. View

Aybay C, Imir T . Comparison of the effects of Salmonella minnesota Re595 lipopolysaccharide, lipid A and monophosphoryl lipid A on nitric oxide, TNF-alpha, and IL-6 induction from RAW 264.7 macrophages. FEMS Immunol Med Microbiol. 1998; 22(3):263-73. DOI: 10.1111/j.1574-695X.1998.tb01215.x. View

Long K, Beatty G . Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology. 2014; 2(12):e26860. PMC: 3902119. DOI: 10.4161/onci.26860. View

Sica A, Mantovani A . Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122(3):787-95. PMC: 3287223. DOI: 10.1172/JCI59643. View

Holtick U, Scheulen M, von Bergwelt-Baildon M, Weihrauch M . Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs. 2011; 20(3):361-72. DOI: 10.1517/13543784.2011.553187. View

Van De Voort T, Felder M, Yang R, Sondel P, Rakhmilevich A . Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2012; 36(1):29-40. PMC: 3521848. DOI: 10.1097/CJI.0b013e3182780f61. View

Sester D, Naik S, Beasley S, Hume D, Stacey K . Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol. 2000; 165(8):4165-73. DOI: 10.4049/jimmunol.165.8.4165. View

Vonderheide R, Flaherty K, Khalil M, Stumacher M, Bajor D, Hutnick N . Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007; 25(7):876-83. DOI: 10.1200/JCO.2006.08.3311. View

Urban J, Shepard H, Rothstein J, Sugarman B, Schreiber H . Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci U S A. 1986; 83(14):5233-7. PMC: 323925. DOI: 10.1073/pnas.83.14.5233. View

10.

Suttles J, Stout R . Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol. 2009; 21(5):257-64. DOI: 10.1016/j.smim.2009.05.011. View

11.

Lu Y, Yeh W, Ohashi P . LPS/TLR4 signal transduction pathway. Cytokine. 2008; 42(2):145-151. DOI: 10.1016/j.cyto.2008.01.006. View

12.

An H, Yu Y, Zhang M, Xu H, Qi R, Yan X . Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology. 2002; 106(1):38-45. PMC: 1782697. DOI: 10.1046/j.1365-2567.2002.01401.x. View

13.

Lum H, Buhtoiarov I, Schmidt B, Berke G, Paulnock D, Sondel P . In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol. 2006; 79(6):1181-92. DOI: 10.1189/jlb.0405191. View

14.

Vonderheide R, Bajor D, Winograd R, Evans R, Bayne L, Beatty G . CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother. 2013; 62(5):949-54. PMC: 3731141. DOI: 10.1007/s00262-013-1427-5. View

15.

MacMicking J, Xie Q, Nathan C . Nitric oxide and macrophage function. Annu Rev Immunol. 1997; 15:323-50. DOI: 10.1146/annurev.immunol.15.1.323. View

16.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

17.

Buhtoiarov I, Lum H, Berke G, Sondel P, Rakhmilevich A . Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol. 2005; 176(1):309-18. DOI: 10.4049/jimmunol.176.1.309. View

18.

Krisher T, Bar-Shavit Z . Regulation of osteoclastogenesis by integrated signals from toll-like receptors. J Cell Biochem. 2014; 115(12):2146-54. DOI: 10.1002/jcb.24891. View

19.

Rakhmilevich A, Buhtoiarov I, Malkovsky M, Sondel P . CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother. 2008; 57(8):1151-60. PMC: 11031017. DOI: 10.1007/s00262-007-0447-4. View

20.

Lum H, Buhtoiarov I, Schmidt B, Berke G, Paulnock D, Sondel P . Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology. 2006; 118(2):261-70. PMC: 1782283. DOI: 10.1111/j.1365-2567.2006.02366.x. View